🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "huge turning point" in the effort against drug-resistant strains of the pathogen, according to health experts.

A Global Health Concern

The sexually transmitted infection are escalating around the world, with data suggesting over 82 million new cases each year. Notably increased rates are observed in the African continent and countries within the WHO's designated area, which spans from China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary advancement in the reality of rising global incidence, escalating drug resistance and the highly restricted available drugs currently available.”

Health officials are deeply concerned about the rise in treatment-resistant strains. The WHO has classified it as a "critical concern". Recent surveillance revealed that the effectiveness of key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Therapies Secure Approval

One new antibiotic, marketed under the name Nuzolvence, was approved by the American regulatory agency in December for combating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Experts believe that focused deployment of this new drug will help delay the emergence of superbugs.

Another new antibiotic, developed by the drugmaker GSK, was also approved in the same week. This drug, which is employed against UTIs, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

This new treatment stemmed from a innovative non-profit model for medication research. The non-profit organisation GARDP partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This milestone marks a significant shift in the therapy of highly resistant gonorrhoea, which until now has been staying ahead of medical innovation.”

Testing Results and Worldwide Availability

Based on results detailed in a major medical journal, zoliflodacin cured the vast majority of genital gonorrhoea infections. This establishes an similar efficacy with the typical regimen, which combines a dual-drug approach. The trial enrolled nearly 1,000 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, the non-profit has the authority to make available and distribute the drug in numerous regions with limited resources.

Doctors directly involved have voiced hope. Access to a one-pill regimen of this kind is described as a "critical tool" for managing the epidemic. This is considered essential to reduce the burden of the disease for patients and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.